Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.

Oncologist · 2024 · PMC10994255 · PMID 37995313

Europe PMC DOI

hedged sentences

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

a favorable trendP = .098so close (0.05 < p ≤ 0.1)

A favorable trend in rwPFS was reported in patients receiving T-DXd as I/II line versus further lines (17 vs. 15 months; P = .098).

also in 313 other papers

did not reach statistical significanceno p-value reported

However, this difference did not reach statistical significance.

also in 24,045 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.